ClinicalTrialsFinder
RecruitingNCT06382519

Thalidomide Therapy for VEOIBD

Thalidomide Therapy for Very Early Onset Inflammatory Bowel Disease

Sponsor

Children's Hospital of Fudan University

Enrollment

40 participants

Start Date

May 15, 2024

Study Type

OBSERVATIONAL

Conditions

Inflammatory Bowel Diseases

Summary

This is a single center, observational study to investigate the clinical outcomes of thalidomide treatment for very early onset inflammatory bowel disease

Eligibility

Min Age: 28 DaysMax Age: 6 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Thalidomide for people with inflammatory bowel diseases. The study is currently recruiting participants at 1 location. People eligible for this study include aged 28 Days to 6 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGThalidomide

thalidomide, dose 1.5-2.5mg/kg.d, orally taken before bedtime.

Locations(1)

Lin Wang

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06382519

Related Trials

BOOM-IBD2 Pivotal Clinical Trial

NCT0657166919 locations

A Database Study of Disease, Treatment Patterns and Healthcare Use in Children With Inflammatory Bowel Diseases in Korea

NCT075207471 location

A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

NCT07012395223 locations

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

NCT06226883226 locations

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

NCT0484460667 locations